Resultados de la búsqueda 551-560 of 13332 for G6PD deficiency
Also eligible are (11) up to 6 donors with triple negative breast cancer and (12) up to 6 donors with colorectal cancer who have no clinical evidence of ...
The purpose of this study is to compare standard chemotherapy to therapy with CPX-351 and/or gilteritinib for patients with newly diagnosed acute myeloid ...
Effective treatments for recurrent gynecological cancer are lacking, and there is a need for novel therapeutic options. One of the barriers to improving ...
Inotuzumab ozogamicin is a monoclonal antibody, called inotuzumab, linked to a type of chemotherapy called calicheamicin. Inotuzumab attaches to cancer cells in ...
Rochester, Minn. The purpose of this study is to obtain serum from patients with certain rare immunobullous diseases (e.g., paraneoplastic pemphigus, laminin- ...
The purpose of this study is to further characterize the serum and Cerebral Spinal Fluid (CSF) biomarker profile of idiopathic normal pressure hydrocephalus, ...
ADPKD is a leading cause of end-stage renal disease. Recently, a new medication called Tolvaptan has been approved by the FDA to slow progression of ADPKD.
This phase III trial studies whether inotuzumab ozogamicin added to post-induction chemotherapy for patients with High-Risk B-cell Acute Lymphoblastic Leukemia ...
The aim of the study is to see how safe, tolerable, and effective the study drug is on its own and in combination with other anti-cancer drugs (bevacizumab, ...
Mayo Clinic no respalda compañías ni productos. Las recaudaciones de los avisos comerciales financian nuestra misión sin fines de lucro.
Consulta estos éxitos de venta y ofertas especiales en libros y boletines informativos de Mayo Clinic Press.
¿Te gustaría hacer una donación deducible de impuestos y ser parte de una investigación de vanguardia y de una atención médica que transforma la medicina?